IMUNON reports 14.7-month OS gain from Phase 2 ovarian cancer trial
IMUNON has presented final overall survival data from its randomised Phase 2 OVATION 2 study of IMNN-001 in newly diagnosed advanced ovarian cancer, reporting a 14.7-month median OS difference versus standard chemotherapy alone. The Lawrenceville, New Jersey-based clinical-stage biotech used its 2026 R&D Day to set out the clinical rationale for its ongoing pivotal Phase 3 programme, OVATION 3, which is enrolling ahead of its internal planning assumptions.
In the 112-patient intent-to-treat population of OVATION 2, women receiving IMNN-001 plus neoadjuvant and adjuvant chemotherapy achieved a median overall survival of 45.1 months, compared with 30.4 months for chemotherapy alone. The gap widened as the dataset matured: the July 2024 interim readout had shown an 11.1-month difference, rising to 14.7 months in the December 2025 final analysis. In the subset of patients who went on to receive PARP inhibitor maintenance, the reported difference was larger still, at 24.2 months (65.6 months versus 41.4 months).
The science behind the signal
IMNN-001 is not a recombinant cytokine. It is an IL-12 DNA plasmid encased in IMUNON's proprietary TheraPlas nanoparticle and delivered intraperitoneally, instructing the patient's own cells to produce IL-12 locally within the peritoneal cavity where advanced ovarian cancer typically disseminates. The approach is designed to sidestep the dose-limiting systemic toxicity that caused earlier recombinant IL-12 programmes to be abandoned in the 1990s.
Chief executive Stacy Lindborg noted that OVATION 2 was not powered for overall survival and that the Phase 3 trial is required to confirm the signal. "A 14.7-month median overall survival difference observed in a 112-patient randomised Phase 2 study represents an important clinical signal that we believe warrants confirmation in a pivotal Phase 3 trial," she said.
Biomarker data from OVATION 1 and OVATION 2 showed increased CD8-positive T-cell and M1 macrophage infiltration alongside reductions in immunosuppressive markers, consistent with a shift from a cold to a hot tumour microenvironment. Preliminary data from a separate Phase 2 minimal residual disease study, conducted in partnership with Break Through Cancer and led by investigators at MD Anderson Cancer Center, showed that 100 per cent of evaluable patients in the IMNN-001 arm had no evidence of disease after frontline therapy versus 56 per cent in the control arm, though sample sizes remain very small and efficacy conclusions cannot yet be drawn.
OVATION 3 and the regulatory path
The pivotal OVATION 3 trial is a randomised 1:1 study targeting approximately 500 patients with newly diagnosed Stage IIIB/C or IV epithelial ovarian, fallopian tube or primary peritoneal cancer. Overall survival is the primary endpoint. IMUNON reported that observed site-level enrolment is running at roughly 0.5 patients per site per month against a planning assumption of 0.3, and the company is targeting full enrolment by the first quarter of 2029. Two pre-planned, event-driven interim analyses could open a pathway to an earlier biologics licence application if the survival signal crosses pre-specified thresholds.
IMNN-001 holds Fast Track and Orphan Drug designations in the United States and orphan status in Europe, designations that provide some regulatory acceleration and market exclusivity protection but do not guarantee approval.
The frontline advanced ovarian cancer space has seen limited progress over a quarter of a century, with platinum-based chemotherapy remaining the backbone of treatment. PARP inhibitors introduced a meaningful option in the maintenance setting, particularly for homologous recombination-deficient patients, but the overall survival benefit at diagnosis has been modest in unselected populations. A locally delivered immunotherapy achieving a durable OS benefit in an all-comers population would represent a genuinely differentiated addition, provided the Phase 3 data hold. Independent data monitoring committees recommended continuation without modification for both OVATION 3 and the MRD study in mid-2026, which removes one near-term risk for investors tracking the programme.